Immunotherapy combo shrinks liver tumors before ablation in early trial
NCT ID NCT03753659
First seen Mar 29, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This study tested whether giving the immunotherapy drug pembrolizumab before and after local ablation (using heat or radiation to destroy tumors) could help shrink liver cancers in 30 patients with early-stage hepatocellular carcinoma. The goal was to see if this approach could make more patients eligible for ablation and delay cancer recurrence. The trial was completed and focused on measuring tumor response and time to recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hannover Medical School
Hanover, Lower Saxony, 30625, Germany
Conditions
Explore the condition pages connected to this study.